Onconova Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Filed herewith.
Furnished herewith.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
| Date: April 1, 2024 | | |
|---|---|---|
| | Onconova Therapeutics, Inc. | |
| | | |
| | By: | /s/ STEVEN M. FRUCHTMAN, M.D. |
| | | Steven M. FruchtmanChief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| | | |||
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | | | |
| /s/ STEVEN M. FRUCHTMAN, M.D. | | Director, President and Chief Executive Officer(Principal Executive Officer) | | April 1, 2024 |
| Steven M. Fruchtman, M.D. | | | | |
| | | | | |
| /s/ MARK GUERIN | | Chief Operating Officer and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | April 1, 2024 |
| Mark Guerin | | | | |
| | | | | |
| /s/ JAMES J. MARINO | | Chairman, Board of Directors | | April 1, 2024 |
| James J. Marino | | | | |
| | | | | |
| /s/ Peter Atadja PH.D. | | Director | | April 1, 2024 |
| Peter Atadja, Ph.D. | | | | |
| | | | | |
| /s/ Trafford Clarke, PH.D. | | Director | | April 1, 2024 |
| Trafford Clarke, Ph.D. | | | | |
| | | | | |
| /s/ JEROME E. GROOPMAN, M.D. | | Director | | April 1, 2024 |
| Jerome E. Groopman, M.D. | | | | |
| | | | | |
| /s/ VIREN MEHTA, PH.D. | | Director | | April 1, 2024 |
| J Viren Mehta, Ph.D. | | | | |
| | | | | |
| /s/ MARY TERESA SHOEMAKER | | Director | | April 1, 2024 |
| Mary Teresa Shoemaker | | | | |
| | | | | |
| /s/ JACK E. STOVER | | Director | | April 1, 2024 |
| Jack E. Stover | | | |
Index to Consolidated Financial Statements
| | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 |
| | |
| Consolidated Balance Sheets, December 31, 2023 and 2022 | F-4 |
| | |
| Consolidated Statements of Operations, Years ended December 31, 2023 and 2022 | F-5 |
| | |
| Consolidated Statements of Comprehensive Loss, Years ended December 31, 2023 and 2022 | F-6 |
| | |
| Consolidated Statements of Stockholders’ Equity, Years ended December 31, 2023 and 2022 | F-7 |
| | |
| Consolidated Statements of Cash Flows, Years ended December 31, 2023 and 2022 | F-8 |
| | |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.